Literature DB >> 34075515

Rituximab- and ocrelizumab-induced early- and late-onset neutropenia in a multiple sclerosis patient.

Mariano Marrodan1, Julia Laviano2, Sofía Oneto3, Fabricio M Reino3, Ricardo Delorme3, Florencia Fornillo2, José Férnandez4,2, Jorge Correale4.   

Abstract

Entities:  

Year:  2021        PMID： 34075515     DOI： 10.1007/s10072-021-05357-1

Source DB:  PubMed          Journal:  Neurol Sci        ISSN： 1590-1874            Impact factor:   3.307


× No keyword cloud information.
  13 in total

1.  The earliest stages of B cell development require a chemokine stromal cell-derived factor/pre-B cell growth-stimulating factor.

Authors:  T Egawa; K Kawabata; H Kawamoto; K Amada; R Okamoto; N Fujii; T Kishimoto; Y Katsura; T Nagasawa
Journal:  Immunity       Date:  2001-08       Impact factor: 31.745

Review 2.  Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms.

Authors:  Daniel Tesfa; Jan Palmblad
Journal:  Expert Rev Hematol       Date:  2011-12       Impact factor: 2.929

3.  B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.

Authors:  Kieron Dunleavy; Frances Hakim; Hyun Kyung Kim; John E Janik; Nicole Grant; Takayuki Nakayama; Therese White; George Wright; Larry Kwak; Ronald Gress; Giovanna Tosato; Wyndham H Wilson
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

4.  Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis.

Authors:  Bruce A Cohen
Journal:  Neurology       Date:  2019-01-11       Impact factor: 9.910

Review 5.  Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: A case report and review of the literature.

Authors:  Chiara Zanetta; Micaela Robotti; Agostino Nozzolillo; Francesca Sangalli; Giuseppe Liberatore; Eduardo Nobile-Orazio; Massimo Filippi; Lucia Moiola
Journal:  J Neurol Sci       Date:  2019-11-28       Impact factor: 3.181

6.  Late-onset neutropenia in a multiple sclerosis patient after first dose ocrelizumab switched from rituximab.

Authors:  Michael Auer; Gabriel Bsteh; Harald Hegen; Sebastian Wurth; Anne Zinganell; Thomas Berger; Florian Deisenhammer; Franziska Di Pauli
Journal:  Mult Scler Relat Disord       Date:  2020-05-13       Impact factor: 4.339

7.  CD8+, CD57+ T cells from healthy elderly subjects suppress neutrophil development in vitro: implications for the neutropenia of Felty's and large granular lymphocyte syndromes.

Authors:  G Coakley; M Iqbal; D Brooks; G S Panayi; J S Lanchbury
Journal:  Arthritis Rheum       Date:  2000-04

8.  Delayed-onset neutropenia associated with rituximab therapy.

Authors:  Kritika Chaiwatanatorn; Newton Lee; Andrew Grigg; Robin Filshie; Frank Firkin
Journal:  Br J Haematol       Date:  2003-06       Impact factor: 6.998

9.  Late-onset neutropenia after RITUXIMAB therapy for multiple sclerosis, neuromyelitis optica spectrum disorders and MOG-antibody-associated diseases.

Authors:  J Rigal; J Ciron; Z Lépine; D Biotti
Journal:  Mult Scler Relat Disord       Date:  2020-02-22       Impact factor: 4.339

10.  Severe Delayed-Onset Neutropenia Induced by Ocrelizumab.

Authors:  Jonatha Baird-Gunning; James Yun; William Stevenson; Karl Ng
Journal:  Neurohospitalist       Date:  2020-07-09
View more
  1 in total

1.  Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.

Authors:  Nicola Capasso; Raffaele Palladino; Vincenza Cerbone; Antonio Luca Spiezia; Bianca Covelli; Antonia Fiore; Roberta Lanzillo; Antonio Carotenuto; Maria Petracca; Lucia Stanziola; Giulia Scalia; Vincenzo Brescia Morra; Marcello Moccia
Journal:  J Neurol       Date:  2022-09-01       Impact factor: 6.682
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.